Business Segments

We are a leading international manufacturer and distributor of pharmaceutical, nutraceutical products and Healthcare products headquartered in Bangkok, Thailand. Currently, we are a leading distributor in developing countries with high growth trends such as Myanmar, Vietnam and Cambodia. In addition, we develop, manufacture, market and sell our own market leading brands of nutraceutical products, generic prescription pharmaceutical products, and OTC products under our Mega We Care™ brand through our distribution network and third party distributors in countries across the world. As of December 31, 2025, our Mega We Care™ branded products were being sold in a total of 34 countries around the world.

Our business activities across all major stages of the pharmaceutical industry value chain provide us with increased opportunities to pursue growth by realizing potential synergies arising from coordinating our efforts across business segments in our selected markets. We believe the market leading positions held by our Mega We Care™ branded products and Maxxcare distribution businesses will enhance our ability to increase market share through both organic growth and acquisitions. In addition, the growth of our business will provide us with sufficient resources to continue developing new products, and allow us to invest in our distribution services to drive and strengthen future growth and profitability.

We believe that significant growth opportunities will arise from our focus on fast growing developing markets. The pharmaceutical and nutraceutical markets in the developing world are expanding rapidly, in line with strong economic growth and demographic changes. The consumer health market in particular is the direct beneficiary of favorable global and local healthcare trends and is expected to grow significantly over the coming years.

Due to the economic growth of the key markets in which we operate, in addition to increased consumer health awareness in those markets, we foresee opportunities and a trend of revenue growth from our major business segments, namely, our Maxxcare distribution business segment and Mega We Care™ branded products business segment.

Mega We Care™ branded products achieved a higher rate of profit than other business segments. Such growth was attributable to increased revenues derived from Mega We Care™ branded products (mainly from the sales of pharmaceutical prescription products, nutraceutical products and OTC products). Revenue from our Maxxcare distribution business-an important business segment with high growth potential, given the growth potential of our customer base (principal) in pharmaceuticals and FMCG.

We Operate in the Following Three Business Segments

Our Maxxcare™ distribution business
We market, sell and distribute various branded prescription pharmaceutical products, OTC and FMCG products. Services include warehouse management, collections (including assuming the liability for bad debts), and value-added services, such as marketing services for some major principals. We operate in Myanmar, Vietnam, and Cambodia. Clients include leading domestic and international pharmaceutical and FMCG companies. In addition, we also distribute our Mega We Care™ branded products in the markets in which we operate.
Our Mega We Care™ branded products business
We develop, manufacture, market and sell our own brand of nutraceutical products, prescription pharmaceutical products and OTC products.
Our OEM business
In addition to manufacturing our own branded products, our manufacturing facilities in Thailand and Australia accepts various production orders from third-party customers. Mega Lifesciences™ revenue is derived mainly from Mega We care Branded products which comprise of Medicinal Supplements and Niche Pharmaceutical products and Maxxcare distribution business. These two businesses contribute more than 98% of the business revenues. Mega Lifesciences also manufactures products under OEM contracts in its facilities located in Thailand and Australia.

Our Growth Strategies

Continue to make investments in capacity building.
We will engage with stakeholders and build a mutual growth platform.
Sustain and grow the revenue streams by introducing specialty Pharmaceutical and Supplement products in our existing and new markets.
We aim to be a champion of developing and underdeveloped markets by introducing high technology / niche products at affordable prices.
We will improve the standards of offerings in products under Mega We care through compliance of higher standards of GMP and in services under Maxxcare by adopting technology and higher standards of services.
Mega Lifesciences will also optimize costs to ensure sustainable existence and growth in the markets where it operates.

Our Resources

high technology manufacturing operations
+
Employees Worldwide
Presence in countries
Trademarks
(Year 2025: 3,975 trademarks)
High value and deep engagement outsourcing contracts for certain niche pharmaceutical products
Deep technology investments for connecting Patients, Health Care Professionals and Pharmacies to improve the healthcare ecosystem

Our Presence

Global Reach

Revenue Breakdown by Region (FY2025)

Southeast Asia Accounts for Majority of Revenues

Branded Products Sales in 34 Countries
  1. Azerbaijan
  2. Congo
  3. Cambodia
  4. Ghana
  5. Hong Kong
  6. Indonesia
  7. Kazakhstan
  8. Kenya
  9. Burundi
  10. Malaysia
  11. Mongolia
  12. Myanmar
  13. Nigeria
  14. Peru
  15. Philippines
  16. Rwanda
  17. Singapore
  18. Sri Lanka
  19. Tanzania
  20. Thailand
  21. Trinidad and Tobago
  22. Uganda
  23. Ukraine
  24. United Arab Emirates
  25. Uzbekistan
  26. Vietnam
  27. Yemen
  28. Ethiopia
  29. Sudan
  30. Nepal
  31. Zambia
  32. Columbia
  33. Zimbabwe
  34. South Sudan

Value addition by Mega Lifesciences and its 5,400+ dedicated employees

Mega Lifesciences believes in creating wealth and distributing wealth among the stakeholders.

Mega Lifesciences believes in rewarding its employees adequately in the form of incentives, stock options, friendly work places and healthcare for all. Mega Lifesciences believes in paying its due share of taxes to the society and has a policy of paying minimum 25% dividend to the shareholders. Mega Lifesciences also invests for the betterment of the society through its wellness we care foundation. Mega Lifesciences pays its suppliers on time and ensures diligent repayment to all the banks and financial institutions on due dates.

Economic Value Added

Direct Economic Value Generated Unit FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Sale revenues Million Baht 14,147 15,344 15,681 15,686 14,136 12,589
Revenues from sale of goods and rendering of services Million Baht 14,147 15,344 15,681 15,686 14,136 12,589
Net sales plus revenues from financial investments and sales of assets Million Baht 14,235 15,409 15,745 15,728 14,149 12,602
Economic Value Distributed
Employee wages and benefits Million Baht 2,626 2,476 2,303 2,404 2,259 2,058
Operating cost Million Baht 5,511 5,342 5,129 5,298 4,686 4,154
Payments to government: Gross taxes Million Baht 374 362 423 389 363 227
Payments to providers of capital: Dividend payments Million Baht 1,395 1,395 1,439 1,404 924 671
Community investments - - - 0.5 7 - -
Economic value retained Million Baht 9,754 9,416 8,841 8,316 7,542 6,497

Mega Lifesciences believes in paying its share of taxes to the society and governments and has in the past received the Thailand Prime Minister's award for best practices in Taxation.

Our subsidiaries in tax havens are purely for the purpose of facilitating our operations and not for the sake of avoidance of taxes.

Reconciliation of Effective Tax Rate

Consolidated
Particulars 2025 2024 2023
Rate (%) Baht Million Rate (%) Baht Million Rate (%) Baht Million
Operating Profits before Income tax expense 2,404 2,352 2,262
Income tax using the expected average tax rate* 20.9 502 19.3 454 17.2 388
Tax effect of income and expense that are not taxable or not deductible in determining taxable profit, net 18 (121) (90)
Others (27) 6 (28)
Total 20.5 492 14.4 340 11.9 269

Remark:

  • * Expected average tax rate corresponds to the weighted average tax rates by operating profits before tax expense in those countries where Mega Operates.
Tax Payment Worldwide as per Consolidated P & L

In 2025

Tax payment worldwide

492 Million Baht

Dividend Payment